This site provides comprehensive information on the funds invested in listed shares by LBO France Gestion.

Please indicate which investor category you belong to:

Jul. 2019

LBO France announces its investment in TRIBVN HEALTHCARE

TRIBVN Healthcare announces a €5m ($5.6m) fundraising campaign financed by LBO France through its Digital Health 2 venture fund. As a major player in digital pathology augmented by artificial intelligence, TRIBVN Healthcare develops a complete imaging software suite combining workstation, diagnostic assistance and telemedicine.

This fundraising will enable TRIBVN Healthcare to become the leader in the digital transition of diagnostic and research laboratories in Europe and North America. TRIBVN Healthcare’s innovation enables its customers to be more efficient and more secure in their practices. These are today the major challenges of diagnosis in the context of increasingly personalized and data driven medicine, particularly in oncology.

In addition to accelerating international business development, the fundraising will enhance CaloPix and TeleSlide solutions by integrating the latest technological innovations from the Cloud and AI. With its experience and roots in the largest clinical and research institutions in Europe and Canada, TRIBVN Healthcare will continue to work and ensure that this digital transformation takes place with physicians and for the benefit of patients, thus creating real and lasting value.

Jean-François Pomerol, CEO of TRIBVN Healthcare, explains: “I am very excited that LBO France is supporting us in the next phase of TRIBVN Healthcare’s development. The professionalism and experience of the venture health team is an undeniable recognition of our know-how and a strong commitment in our ability to transform cellular diagnostics at an international scale. The funding will allow us to increase the added value of our solutions and provide effective solutions to the problems faced by laboratories.”

Sébastien Woynar, Investment Director at LBO France, adds: “Artificial intelligence enhanced digital pathology is revolutionizing pathology and several medical specialties, such as oncology. TRIBVN Healthcare has a remarkable understanding of the field of pathology and a deep product portfolio, key success factors to build a global footprint. This support strengthens TRIBVN Healthcare’s ability to be, on a global scale, the privileged partner of pathology laboratories and research centers.”

About TRIBVN Healthcare:

TRIBVN Healthcare develops software solutions for digital pathology. Innovative and validated, they allow the management, analysis and sharing of cellular images both for diagnostic laboratories and pharmaceutical & biotech manufacturers.

In the field of image analysis, our solutions are based on the latest innovations in terms of artificial intelligence, notably deep and machine learning algorithms. These tools support physicians and researchers in their diagnostic decision-making and scientific evaluation for the sake of patients.

In the field of sharing, our solutions implement full web tools to support our customers in their telepathology, teaching or multi-centric clinical validation activities.

Find out more:

Contact: Jean-François Pomerol – CEO –

Media Contact: Pauline Baldo, Marketing & Communication manager – – +33 1 55 58 05 35

About LBO France:

As a key player in private equity with €4bn of capital under management, LBO France is an independent company that has been supporting European companies in their growth for more than 30 years. Its investment strategy is built on 4 distinct segments managed by dedicated teams: (i) Mid Cap Buyout through the White Knight funds and Small Cap Buyout through the Hexagone/Small Caps Opportunities funds, (ii) Venture Capital through the SISA/Digital Health funds, (iii) Real Estate through the White Stone and Lapillus funds, (iv) Debt. LBO France is 100% owned by its management and employs nearly 60 professionals.

Find out more:

Contact: Sébastien Woynar, Investment Director –

Media Contact:

Agence Shan

Léa Schultz – + 33 1 42 86 82 41 –

Laetitia Hottinguer – + 33 1 44 50 58 78 –



Read Press Release